Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Affiliations

¹ Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany. h.salwender@asklepios.com.
² Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany.
³ Department of Hematology, Celltherapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
⁴ Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
⁵ Klinikum Chemnitz, Chemnitz, Germany.
⁶ Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
⁷ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
⁸ Charité Universitätsmedizin, Berlin, Germany.
⁹ University Hospital Cologne, Cologne, Germany.
¹⁰ Vrije Universiteit Brussel (VUB), Laboratory of Hematology and Immunology & Labor für Myelomforschung, Jette, Belgium.
¹¹ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
¹² Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
¹³ University Hospital Tubingen, Tubingen, Germany.
¹⁴ University Medical Center Mainz, Mainz, Germany.
¹⁵ University Hospital Bonn, Bonn, Germany.
¹⁶ Helios Hospital Berlin Buch, Buch, Germany.
¹⁷ Kath. Krankenhaus Hagen, Hagen, Germany.
¹⁸ University Hospital Hamburg, Hamburg, Germany.
¹⁹ University Hospital Essen, Essen, Germany.

Clinical Trial

Hans Salwender et al. Leukemia. 2021 Oct.

. 2021 Oct;35(10):3007-3011.

doi: 10.1038/s41375-021-01298-y. Epub 2021 May 24.

¹ Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg, Germany. h.salwender@asklepios.com.
² Department of Hematology/Oncology and Stem Cell Transplantation, AK St. Georg, Hamburg, Germany.
³ Department of Hematology, Celltherapy and Hemostaseology, University Hospital of Leipzig, Leipzig, Germany.
⁴ Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
⁵ Klinikum Chemnitz, Chemnitz, Germany.
⁶ Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
⁷ National Center for Tumor Diseases (NCT), Heidelberg, Germany.
⁸ Charité Universitätsmedizin, Berlin, Germany.
⁹ University Hospital Cologne, Cologne, Germany.
¹⁰ Vrije Universiteit Brussel (VUB), Laboratory of Hematology and Immunology & Labor für Myelomforschung, Jette, Belgium.
¹¹ Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany.
¹² Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany.
¹³ University Hospital Tubingen, Tubingen, Germany.
¹⁴ University Medical Center Mainz, Mainz, Germany.
¹⁵ University Hospital Bonn, Bonn, Germany.
¹⁶ Helios Hospital Berlin Buch, Buch, Germany.
¹⁷ Kath. Krankenhaus Hagen, Hagen, Germany.
¹⁸ University Hospital Hamburg, Hamburg, Germany.
¹⁹ University Hospital Essen, Essen, Germany.

No abstract available

References

1. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385:2197–208. - DOI
1. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40. - DOI
1. Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97:1925–8. - DOI
1. Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29:1721–9. - DOI
1. Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34:1853–65. - DOI